Allspring Global Investments Holdings LLC Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Allspring Global Investments Holdings LLC lifted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,862 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,192 shares during the period. Allspring Global Investments Holdings LLC owned about 0.14% of Collegium Pharmaceutical worth $1,412,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 2,877 shares during the period. Versor Investments LP acquired a new position in Collegium Pharmaceutical during the third quarter worth $207,000. Ritholtz Wealth Management purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at $286,000. SG Americas Securities LLC acquired a new stake in shares of Collegium Pharmaceutical in the third quarter valued at about $221,000. Finally, O Shaughnessy Asset Management LLC increased its stake in shares of Collegium Pharmaceutical by 14.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company’s stock worth $257,000 after purchasing an additional 1,440 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on COLL. Truist Financial raised their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Piper Sandler reiterated an “overweight” rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Needham & Company LLC restated a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 29th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $34.74 on Tuesday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The firm has a market capitalization of $1.14 billion, a P/E ratio of 29.44 and a beta of 1.03. The stock’s fifty day moving average is $36.90 and its two-hundred day moving average is $31.03. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The firm had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. On average, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.